Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1263 entries
Sorted by: Best Match Show Resources per page
Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.

Medical oncology (Northwood, London, England)

Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V.
PMID: 28382591
Med Oncol. 2017 May;34(5):79. doi: 10.1007/s12032-017-0925-2.

No abstract available.

Cite
Scevola G, Loreni G, Rastelli M, et al. Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med Oncol. 2017;34(5):79doi: 10.1007/s12032-017-0925-2.
Scevola, G., Loreni, G., Rastelli, M., Sposato, S., Ramponi, S., & Miele, V. (2017). Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Medical oncology (Northwood, London, England), 34(5), 79. https://doi.org/10.1007/s12032-017-0925-2
Scevola, Germano, et al. "Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization." Medical oncology (Northwood, London, England) vol. 34,5 (2017): 79. doi: https://doi.org/10.1007/s12032-017-0925-2
Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V. Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med Oncol. 2017 May;34(5):79. doi: 10.1007/s12032-017-0925-2. PMID: 28382591.
Copy Download .nbib Format: NLM
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Therapeutic advances in medical oncology

Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK.
PMID: 25755678
Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117.

OBJECTIVES: ALK-EML4 translocation is an established driver aberration in non-small cell lung cancer (NSCLC), with reported predilection for cases with signet ring histology. We assessed the presence of anaplastic lymphoma kinase (ALK) gene rearrangements in signet ring cancers arising...

Cite
Alese OB, El-Rayes BF, Sica G, et al. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015;7(2):56-62doi: 10.1177/1758834014567117.
Alese, O. B., El-Rayes, B. F., Sica, G., Zhang, G., Alexis, D., La Rosa, F. G., Varella-Garcia, M., Chen, Z., Rossi, M. R., Adsay, N. V., Khuri, F. R., & Owonikoko, T. K. (2015). Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic advances in medical oncology, 7(2), 56-62. https://doi.org/10.1177/1758834014567117
Alese, Olatunji B, et al. "Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract." Therapeutic advances in medical oncology vol. 7,2 (2015): 56-62. doi: https://doi.org/10.1177/1758834014567117
Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117. PMID: 25755678; PMCID: PMC4346214.
Copy Download .nbib Format: NLM
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.

Therapeutic advances in medical oncology

Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G.
PMID: 28344663
Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11.

Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this...

Cite
Pusceddu S, Verzoni E, Prinzi N, et al. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Ther Adv Med Oncol. 2017;9(3):183-188doi: 10.1177/1758834016683905.
Pusceddu, S., Verzoni, E., Prinzi, N., Mennitto, A., Femia, D., Grassi, P., Concas, L., Vernieri, C., Lo Russo, G., & Procopio, G. (2017). Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Therapeutic advances in medical oncology, 9(3), 183-188. https://doi.org/10.1177/1758834016683905
Pusceddu, Sara, et al. "Everolimus treatment for neuroendocrine tumors: latest results and clinical potential." Therapeutic advances in medical oncology vol. 9,3 (2017): 183-188. doi: https://doi.org/10.1177/1758834016683905
Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11. PMID: 28344663; PMCID: PMC5349426.
Copy Download .nbib Format: NLM
Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.

Therapeutic advances in medical oncology

Hilal T.
PMID: 28344664
Ther Adv Med Oncol. 2017 Mar;9(3):189-199. doi: 10.1177/1758834016678149. Epub 2016 Nov 17.

Neuroendocrine tumors (NETs) are rare neoplasms that can arise from any tissue. They are classified based on embryonic gut derivative (i.e. foregut, midgut and hindgut) with midgut tumors being the most common (e.g. gastrointestinal NET). The second most common...

Cite
Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2016;9(3):189-199doi: 10.1177/1758834016678149.
Hilal, T. (2017). Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Therapeutic advances in medical oncology, 9(3), 189-199. https://doi.org/10.1177/1758834016678149
Hilal, Talal. "Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management." Therapeutic advances in medical oncology vol. 9,3 (2017): 189-199. doi: https://doi.org/10.1177/1758834016678149
Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol. 2017 Mar;9(3):189-199. doi: 10.1177/1758834016678149. Epub 2016 Nov 17. PMID: 28344664; PMCID: PMC5349423.
Copy Download .nbib Format: NLM
Erratum.

Therapeutic advances in medical oncology

[No authors listed]
PMID: 28344666
Ther Adv Med Oncol. 2017 Mar;9(3):217. doi: 10.1177/1758834017695909. Epub 2017 Feb 01.

[This corrects the article DOI: 10.1177/1758834016659825.].

Cite
Erratum. Ther Adv Med Oncol. 2017;9(3):217doi: 10.1177/1758834017695909.
(2017). Erratum. Therapeutic advances in medical oncology, 9(3), 217. https://doi.org/10.1177/1758834017695909
"Erratum." Therapeutic advances in medical oncology vol. 9,3 (2017): 217. doi: https://doi.org/10.1177/1758834017695909
Erratum. Ther Adv Med Oncol. 2017 Mar;9(3):217. doi: 10.1177/1758834017695909. Epub 2017 Feb 01. PMID: 28344666; PMCID: PMC5349429.
Copy Download .nbib Format: NLM
Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.

Therapeutic advances in medical oncology

Martin P, Leighl NB.
PMID: 28607579
Ther Adv Med Oncol. 2017 Jun;9(6):405-414. doi: 10.1177/1758834017704329. Epub 2017 Apr 26.

This article considers the use of pretest probability in non-small cell lung cancer (NSCLC) and how its use in

Cite
Martin P, Leighl NB. Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Ther Adv Med Oncol. 2017;9(6):405-414doi: 10.1177/1758834017704329.
Martin, P., & Leighl, N. B. (2017). Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Therapeutic advances in medical oncology, 9(6), 405-414. https://doi.org/10.1177/1758834017704329
Martin, Petra, and Leighl, Natasha B. "Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice." Therapeutic advances in medical oncology vol. 9,6 (2017): 405-414. doi: https://doi.org/10.1177/1758834017704329
Martin P, Leighl NB. Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Ther Adv Med Oncol. 2017 Jun;9(6):405-414. doi: 10.1177/1758834017704329. Epub 2017 Apr 26. PMID: 28607579; PMCID: PMC5455881.
Copy Download .nbib Format: NLM
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.

Therapeutic advances in medical oncology

Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA.
PMID: 29449894
Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19.

BACKGROUND: Regorafenib (REG) has now been approved as the standard third-line therapy in metastatic gastrointestinal stromal tumour (GIST) patients at the recommended dose and schedule of 160 mg once daily for the first 3 weeks of each 4-week cycle....

Cite
Nannini M, Nigro MC, Vincenzi B, et al. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Adv Med Oncol. 2017;9(12):731-739doi: 10.1177/1758834017742627.
Nannini, M., Nigro, M. C., Vincenzi, B., Fumagalli, E., Grignani, G., D'Ambrosio, L., Badalamenti, G., Incorvaia, L., Bracci, R., Gasperoni, S., Saponara, M., Gatto, L., Indio, V., Astolfi, A., Di Scioscio, V., Casali, P. G., Tonini, G., Aglietta, M., Russo, A., Biasco, G., & Pantaleo, M. A. (2017). Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic advances in medical oncology, 9(12), 731-739. https://doi.org/10.1177/1758834017742627
Nannini, Margherita, et al. "Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice." Therapeutic advances in medical oncology vol. 9,12 (2017): 731-739. doi: https://doi.org/10.1177/1758834017742627
Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19. PMID: 29449894; PMCID: PMC5808843.
Copy Download .nbib Format: NLM
Erratum to: knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5,637 cells in vitro and in vivo.

Medical oncology (Northwood, London, England)

Gan Y, Tan J, Yang J, Zhou Y, Dai Y, He L, Yao K, Tang Y.
PMID: 25895598
Med Oncol. 2015 May;32(5):161. doi: 10.1007/s12032-015-0611-1.

No abstract available.

Cite
Gan Y, Tan J, Yang J, et al. Erratum to: knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5,637 cells in vitro and in vivo. Med Oncol. 2015;32(5):161doi: 10.1007/s12032-015-0611-1.
Gan, Y., Tan, J., Yang, J., Zhou, Y., Dai, Y., He, L., Yao, K., & Tang, Y. (2015). Erratum to: knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5,637 cells in vitro and in vivo. Medical oncology (Northwood, London, England), 32(5), 161. https://doi.org/10.1007/s12032-015-0611-1
Gan, Yu, et al. "Erratum to: knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5,637 cells in vitro and in vivo." Medical oncology (Northwood, London, England) vol. 32,5 (2015): 161. doi: https://doi.org/10.1007/s12032-015-0611-1
Gan Y, Tan J, Yang J, Zhou Y, Dai Y, He L, Yao K, Tang Y. Erratum to: knockdown of HMGN5 suppresses the viability and invasion of human urothelial bladder cancer 5,637 cells in vitro and in vivo. Med Oncol. 2015 May;32(5):161. doi: 10.1007/s12032-015-0611-1. PMID: 25895598.
Copy Download .nbib Format: NLM
Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review.

Therapeutic advances in medical oncology

Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A.
PMID: 26673925
Ther Adv Med Oncol. 2015 May;7(3):153-69. doi: 10.1177/1758834015572343.

Systemic therapy is the standard care for patients with unresectable advanced colorectal cancer (CRC), but salvage surgery of metastatic disease should be considered in the case of adequate tumor shrinkage. Several drugs and combinations are now available for use...

Cite
Chibaudel B, Tournigand C, Bonnetain F, et al. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol. 2015;7(3):153-69doi: 10.1177/1758834015572343.
Chibaudel, B., Tournigand, C., Bonnetain, F., Richa, H., Benetkiewicz, M., André, T., & de Gramont, A. (2015). Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Therapeutic advances in medical oncology, 7(3), 153-69. https://doi.org/10.1177/1758834015572343
Chibaudel, Benoist, et al. "Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review." Therapeutic advances in medical oncology vol. 7,3 (2015): 153-69. doi: https://doi.org/10.1177/1758834015572343
Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol. 2015 May;7(3):153-69. doi: 10.1177/1758834015572343. PMID: 26673925; PMCID: PMC4406914.
Copy Download .nbib Format: NLM
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.

Therapeutic advances in medical oncology

Grossmann KF, Margolin K.
PMID: 26673806
Ther Adv Med Oncol. 2015 May;7(3):181-91. doi: 10.1177/1758834015572284.

Historically, stage III-IV melanoma patients have had few options to achieve long-term survival. For patients with stage III disease, surgery alone may be curative for approximately 50%. Adjuvant treatment with a slightly greater impact on relapse-free survival at the...

Cite
Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol. 2015;7(3):181-91doi: 10.1177/1758834015572284.
Grossmann, K. F., & Margolin, K. (2015). Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Therapeutic advances in medical oncology, 7(3), 181-91. https://doi.org/10.1177/1758834015572284
Grossmann, Kenneth F, and Margolin, Kim. "Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications." Therapeutic advances in medical oncology vol. 7,3 (2015): 181-91. doi: https://doi.org/10.1177/1758834015572284
Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol. 2015 May;7(3):181-91. doi: 10.1177/1758834015572284. PMID: 26673806; PMCID: PMC4406913.
Copy Download .nbib Format: NLM
Advances in thyroid cancer treatment: latest evidence and clinical potential.

Therapeutic advances in medical oncology

Alonso-Gordoa T, Díez JJ, Durán M, Grande E.
PMID: 25553081
Ther Adv Med Oncol. 2015 Jan;7(1):22-38. doi: 10.1177/1758834014551936.

Advanced thyroid carcinoma is an infrequent tumor entity with limited treatment possibilities until recently. The extraordinary improvement in the comprehension of genetic and molecular alterations involving the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositide 3-kinase/Akt/mammalian target of rapamycin signaling and interacting...

Cite
Alonso-Gordoa T, Díez JJ, Durán M, et al. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(1):22-38doi: 10.1177/1758834014551936.
Alonso-Gordoa, T., Díez, J. J., Durán, M., & Grande, E. (2015). Advances in thyroid cancer treatment: latest evidence and clinical potential. Therapeutic advances in medical oncology, 7(1), 22-38. https://doi.org/10.1177/1758834014551936
Alonso-Gordoa, T, et al. "Advances in thyroid cancer treatment: latest evidence and clinical potential." Therapeutic advances in medical oncology vol. 7,1 (2015): 22-38. doi: https://doi.org/10.1177/1758834014551936
Alonso-Gordoa T, Díez JJ, Durán M, Grande E. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Jan;7(1):22-38. doi: 10.1177/1758834014551936. PMID: 25553081; PMCID: PMC4265091.
Copy Download .nbib Format: NLM
Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature.

Therapeutic advances in medical oncology

Quidde J, Azémar M, Bokemeyer C, Arnold D, Stein A.
PMID: 27239232
Ther Adv Med Oncol. 2016 May;8(3):144-52. doi: 10.1177/1758834016637585. Epub 2016 Mar 17.

BACKGROUND: Treatment of patients with severe liver dysfunction including hyperbilirubinemia secondary to liver metastases of gastrointestinal (GI) cancer is challenging. Regimen of oxaliplatin and fluoropyrimidine (FP)/folinic acid (FA) ± a monoclonal antibody (moAb), represents a feasible option considering the...

Cite
Quidde J, Azémar M, Bokemeyer C, et al. Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. Ther Adv Med Oncol. 2016;8(3):144-52doi: 10.1177/1758834016637585.
Quidde, J., Azémar, M., Bokemeyer, C., Arnold, D., & Stein, A. (2016). Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. Therapeutic advances in medical oncology, 8(3), 144-52. https://doi.org/10.1177/1758834016637585
Quidde, Julia, et al. "Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature." Therapeutic advances in medical oncology vol. 8,3 (2016): 144-52. doi: https://doi.org/10.1177/1758834016637585
Quidde J, Azémar M, Bokemeyer C, Arnold D, Stein A. Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature. Ther Adv Med Oncol. 2016 May;8(3):144-52. doi: 10.1177/1758834016637585. Epub 2016 Mar 17. PMID: 27239232; PMCID: PMC4872252.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1263 entries